Added to YB: 2026-06-22
Pitch date: 2026-06-18
MEDCL.PA [neutral]
MedinCell S.A.
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
Market Cap
EUR 864.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-100.27
P/E
-38.01
EV/Sales
27.27
Sector
Pharmaceuticals
Category
growth
Medincell (MEDCL France): The upcoming ramp-up should sustain the momentum
MEDCL.PA (update): FY rev €24.3m (down on prior-yr one-off milestones), but recurring royalties shifting higher-margin: UZEDY €9.3m (+42% yoy) on Teva +54% sales; partnership rev €10.2m (€6.4m AbbVie). Op loss €20.8m, net loss €31.3m, €24.6m burn; €84.8m cash post €48.2m raise. UZEDY now approved in bipolar; olanzapine LAI FDA decision Q4 2026; AbbVie first clinical pushed to 2027. 10+ programs add optionality.
Read full article (2 min)